阿莫西林/克拉维酸钾治疗下呼吸道感染70例

Efficacy of Amoxicillin/Clavulanate Potassium in Treating Lower Respiratory Tract Infection (70 Cases)

目的 :观察阿莫西林 克拉维酸钾治疗下呼吸道感染的临床疗效。方法 :13 0例患者随机分为治疗组 70例 ,给予阿莫西林 克拉维酸钾咀嚼片 0 .5g ,tid ;对照组 60例 ,给予头孢克洛片 0 .2 5g ,tid。疗程均为 7～ 14d。比较两者临床疗效及安全性。结果 :治疗组与对照组的用药天数分别为 (9.5± 3 .3 )和 (9.1± 3 .3 )d ,两组差异无显著性 (P >0 .0 5 ) ;治疗组有效率为 92 .8% ,对照组 80 .0 % ,两组差异有显著性 (P <0 .0 5 ) ;治疗组细菌清除率 91.4% ,对照组 71.6% ,两组差异有极显著性 (P <0 .0 1)。治疗期间未见明显不良反应。结论 :阿莫西林 克拉维酸钾治疗下呼吸道感染疗效较好 ,安全 ,值得推广。

Objective:To study the therapeutical efficacy of amoxicillin/clavulanate potassium chewable tablets (CPA) in treating lower respiratory tract infection by comparing with the efficacy of cefaclor. Methods:A total of 130 patients were randomly divided into two groups: 70 patients in the treatment group received CPA 0.5 g tid; 60 patients as the control group received cefaclor 0.25 g tid, both for 7～14 days. The efficacy and safety of the two groups were evaluated. Results:Therapeutic courses of the treatment group and the control groups lasted (9.5±3.3) days and (9.1±3.3) days respectively. There was no statistically significant difference ( P >0.05). Effective rate of the treatment group was 92.8%, and that of the control group was 80.0%. Bacterial clearance rates of the two groups were 91.4% and 71.6% respectively. No obvious adverse reaction was found during the therapeutical period. Conclusion:Amoxicillin/clavulanate potassium has a good therapeutical effect in treating lower respiratory tract infection with safety. It is worthy of spreading.